| scholarly article | Q13442814 |
| P50 | author | Jan Holmgren | Q5811529 |
| P2093 | author name string | A-M Svennerholm | |
| S Raghavan | |||
| P2860 | cites work | Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection | Q73535248 |
| Further development of the Helicobacter pylori mouse vaccination model | Q73713363 | ||
| Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria | Q73760558 | ||
| Human gastric B cell responses can be induced by intestinal immunisation | Q28353967 | ||
| Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration | Q29547429 | ||
| A simplification of the protein assay method of Lowry et al. which is more generally applicable | Q29615220 | ||
| Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects | Q33654645 | ||
| Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits | Q33829995 | ||
| Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice. | Q34001758 | ||
| Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate | Q34004684 | ||
| Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia | Q34233479 | ||
| Long term serological surveillance after treatment of Helicobacter pylori infection | Q34394708 | ||
| Helicobacter pylori and the pathogenesis of gastroduodenal inflammation | Q34631374 | ||
| Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study | Q35365282 | ||
| Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses | Q36401349 | ||
| Helicobacter pylori and peptic ulceration: histopathological aspects | Q37362501 | ||
| Urease-associated heat shock protein of Helicobacter pylori | Q37893189 | ||
| Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions | Q39509321 | ||
| Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994 | Q39605655 | ||
| Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection | Q39831682 | ||
| Cell-cell interactions in conjugating Escherichia coli: role of F pili and fate of mating aggregates | Q39991006 | ||
| Identification of Helicobacter pylori by immunological dot blot method based on reaction of a species-specific monoclonal antibody with a surface-exposed protein. | Q40006883 | ||
| Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture | Q40427269 | ||
| Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load | Q41077491 | ||
| Helicobacter pylori and duodenal ulcer recurrence | Q41141467 | ||
| Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes | Q41612852 | ||
| Purification and characterization of urease from Helicobacter pylori | Q43729113 | ||
| Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy | Q44062758 | ||
| Development of a mouse model of Helicobacter pylori infection that mimics human disease | Q44933673 | ||
| Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization | Q52077597 | ||
| After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. | Q53966302 | ||
| Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study | Q58236244 | ||
| A small animal model of human Helicobacter pylori active chronic gastritis | Q68552775 | ||
| Helicobacter pylori and peptic ulcer disease | Q70121033 | ||
| Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice | Q71120560 | ||
| Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4 | Q71828924 | ||
| Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets | Q71884828 | ||
| Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice | Q72349061 | ||
| A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain | Q73212144 | ||
| Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies | Q73395739 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholera | Q12090 |
| Helicobacter pylori | Q180556 | ||
| Helicobacter pylori infectious disease | Q4497153 | ||
| P304 | page(s) | 4621-4627 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis | |
| P478 | volume | 70 |
| Q36826907 | A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection |
| Q82831287 | A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori |
| Q45111137 | Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice |
| Q91015207 | An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses |
| Q47239334 | Antigen-specific in vitro suppression of murine Helicobacter pylori-reactive immunopathological T cells by CD4CD25 regulatory T cells |
| Q37207506 | Antigen-specific regulatory T cells in bovine paratuberculosis |
| Q40155856 | Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori. |
| Q46811625 | Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae |
| Q35689712 | Defining the Roles of IFN-γ and IL-17A in Inflammation and Protection against Helicobacter pylori Infection. |
| Q37559634 | Development of vaccines against Helicobacter pylori |
| Q35923188 | Effect of bacterial flora on postimmunization gastritis following oral vaccination of mice with Helicobacter pylori heat shock protein 60. |
| Q37230001 | Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine |
| Q34334207 | HpaA is essential for Helicobacter pylori colonization in mice |
| Q54347312 | Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit. |
| Q36320323 | Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections |
| Q83198656 | Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice |
| Q79614733 | Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses |
| Q53640412 | Oral vaccination against Helicobacter pylori infection is not effective in mice with Fas ligand deficiency. |
| Q34941937 | Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection |
| Q91010286 | Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant |
| Q35157686 | Priming and expression of immune responses in the gastric mucosa |
| Q36794861 | Progress in vaccine development against Helicobacter pylori |
| Q34529454 | Proinflammatory Cytokine Gene Expression in the Stomach Correlates with Vaccine-Induced Protection against Helicobacter pylori Infection in Mice: an Important Role for Interleukin-17 during the Effector Phase |
| Q34186333 | Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines |
| Q83102402 | Recombinant Mycobacterium smegmatis mc(2)155 vaccine expressing outer membrane protein 26 kDa antigen affords therapeutic protection against Helicobacter pylori infection |
| Q50030181 | Strain dependent protection conferred by Lactobacillus spp. administered orally with a Salmonella Typhimurium vaccine in a murine challenge model. |
| Q24594741 | Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach |
| Q46734851 | The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice |
| Q90011814 | The frequency of circulating integrin α4β7+ cells correlates with protection against Helicobacter pylori infection in immunized mice |
| Q47788853 | Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model |
Search more.